Melanotan I (Afamelanotide) Subcutaneous Implant , Safety & Clinical Use
Afamelanotide (Melanotan I)
Afamelanotide (Melanotan I) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), studied for its role in skin pigmentation, photoprotection, and melanogenesis. It is the clinically approved form of Melanotan I used in specific medical conditions.
How It Works
MC1R Activation → Melanin Production ↑ → UV Protection ↑ + Skin Pigmentation ↑
Afamelanotide activates melanocortin-1 receptors (MC1R) in the skin, increasing melanin production. This leads to enhanced pigmentation and provides a protective effect against ultraviolet (UV) radiation by reducing DNA damage from sun exposure.
Approved Clinical Use
Used medically for erythropoietic protoporphyria (EPP)
Administered as a subcutaneous implant
Each implant contains 16 mg afamelanotide
Implant slowly releases peptide over time
Unlike typical peptide protocols, Afamelanotide is not administered as a daily injection. It is delivered through a long-acting implant designed for controlled release under medical supervision.
Important Distinction
Afamelanotide = clinically approved implant-based therapy
Melanotan I (research market) ≠ standardized medical product
Does not follow standard reconstitution or insulin-syringe dosing
Why It Doesn’t Fit Standard Peptide Protocols
- Not designed for daily or weekly injection use
- No standardized mg → unit conversion like other peptides
- Delivered via controlled-release implant in clinical settings
- Research-market versions vary widely in purity and dosing
Potential Benefits (Research Context)
- Increased skin pigmentation
- Improved UV tolerance and photoprotection
- Reduced photosensitivity in certain conditions
- May support skin resilience to environmental stress
Potential Risks & Considerations
- Skin darkening and uneven pigmentation
- Freckling or mole changes
- Unknown dosing consistency in non-clinical products
- Limited long-term safety data outside clinical use
Important Notes
- This compound is not used like standard injectable peptides
- Clinical use differs significantly from research-market use
- Product quality and dosing variability are major concerns
- Understanding the distinction between approved vs research use is critical
Important Disclaimer
Afamelanotide is approved in certain regions for specific medical conditions and is not FDA-approved for general use in the United States. Research-market Melanotan I products are not regulated. This content is for educational and informational purposes only.
Peptide Directory →
Comments
Post a Comment